Nootropic Agents
Research News and Information

Saturday, November 21, 2009

Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report.

30 Aug 2009 Cognitive deficits are commonly associated with maintenance electroconvulsive therapy (ECT). Treatment of these cognitive deficits is important but difficult. Cholinergic pathways are involved in these side effects, and donepezil, a cholinesterase ... Read more...

Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation.

30 Aug 2009 Galantamine, a novel Alzheimer's drug, is known to inhibit acetylcholinesterase activity and potentiate nicotinic acetylcholine receptor (nAChR) in the brain. We previously reported that galantamine potentiates the NMDA-induced currents in primary ... Read more...

[Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs]

30 Jul 2009 Although there are already many reports about the usefulness of positron emission tomography with FDG (FDG-PET) in diagnosis of Alzheimer disease (AD) and scientific evidence has been established, further improvement in diagnostic ability is ... Read more...

Latest indexed articles for 'Nootropic Agents'

These are the very latest articles for this heading:

• Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Nov 2009
• Turbocharging the brain. 29 Sep 2009
• [Final report is now available. IQWiG doubts the effectiveness of memantine] 22 Sep 2009
• Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report. 30 Aug 2009
• Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. 30 Aug 2009
• Medication for dementia. 30 Aug 2009
• [Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs] 30 Jul 2009
• Treatment of mild cognitive impairment (MCI). 30 Jul 2009
• Acute cognitive effects of donepezil in young, healthy volunteers. 30 Jul 2009
• The inhibitory avoidance test optimized for discovery of cognitive enhancers. 30 Jul 2009
• The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. 30 Jul 2009
• Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. 30 Jul 2009
• DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. 22 Jul 2009
• Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice. 13 Jul 2009
• Recovery of cognitive dysfunction in a case of delayed encephalopathy of carbon monoxide poisoning after treatment with donepezil hydrochloride. 29 Jun 2009
• [Cytoprotective effect of neuropeptides on immunocompetent cells (in vitro study)] 29 Jun 2009
• [Neuro-enhancement. Brain doping] 29 Jun 2009
• [Neuro-enhancement from an addiction specialist's viewpoint] 29 Jun 2009
• Response to "Results, rhetoric, and randomized trials: the case of donepezil". 29 Jun 2009
• Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. 22 Jun 2009

See a longer list of these articles.

Technical information about 'Nootropic Agents'

Definition: Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Registry Number: 0

Descriptor UI: D018697

Alternative terms: Nootropic Agents; Agents, Nootropic; Nootropics; Cognitive Enhancers; Enhancers, Cognitive; Nootropic Drugs; Drugs, Nootropic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.427.637;

Online Note: use PSYCHOTROPIC DRUGS to search NOOTROPIC DRUGS 1990-94

History Note: 95; NOOTRPIC DRUGS was see PSYCHOTROPIC DRUGS 1990-94

Technical Notes: CNS agents; from Greek nous, mind; GEN or unspecified: prefer specifics